Revelation Biosciences, Inc. (REVB)
1.01
0.00 (0.00%)
USD |
NASDAQ |
Sep 09, 13:06
Revelation Biosciences Enterprise Value : -6.795M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | -6.795M |
| September 04, 2026 | -6.795M |
| September 03, 2026 | -6.795M |
| September 02, 2026 | -6.834M |
| September 01, 2026 | -6.887M |
| August 31, 2026 | -6.834M |
| August 28, 2026 | -6.639M |
| August 27, 2026 | -6.717M |
| August 26, 2026 | -7.010M |
| August 25, 2026 | -6.834M |
| August 24, 2026 | -6.444M |
| August 21, 2026 | -6.483M |
| August 20, 2026 | -6.561M |
| August 19, 2026 | -6.405M |
| August 18, 2026 | -6.405M |
| August 17, 2026 | -6.248M |
| August 14, 2026 | -6.643M |
| August 13, 2026 | -6.405M |
| August 12, 2026 | -6.405M |
| August 11, 2026 | -6.326M |
| August 10, 2026 | -6.326M |
| August 07, 2026 | -6.287M |
| August 06, 2026 | -6.366M |
| August 05, 2026 | -6.248M |
| August 04, 2026 | -6.326M |
| Date | Value |
|---|---|
| August 03, 2026 | -6.756M |
| July 31, 2026 | -7.030M |
| July 30, 2026 | -6.853M |
| July 29, 2026 | -6.973M |
| July 28, 2026 | -6.686M |
| July 27, 2026 | -6.60M |
| July 24, 2026 | -6.60M |
| July 23, 2026 | -6.561M |
| July 22, 2026 | -6.248M |
| July 21, 2026 | -6.248M |
| July 20, 2026 | -6.209M |
| July 17, 2026 | -6.131M |
| July 16, 2026 | -6.326M |
| July 15, 2026 | -6.483M |
| July 14, 2026 | -6.678M |
| July 13, 2026 | -6.886M |
| July 10, 2026 | -6.834M |
| July 09, 2026 | -6.932M |
| July 08, 2026 | -6.959M |
| July 07, 2026 | -6.874M |
| July 06, 2026 | -6.756M |
| July 02, 2026 | -6.522M |
| July 01, 2026 | -6.678M |
| June 30, 2026 | -6.717M |
| June 29, 2026 | -9.290M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Shuttle Pharmaceuticals Holdings, Inc. | 1.089M |
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Agenus, Inc. | 581.29M |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Amgen, Inc. | 255.86B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.323M |
| Total Expenses (Quarterly) | 3.323M |
| EPS Diluted (Quarterly) | -0.8679 |
| Earnings Yield | -1.22K% |
| Normalized Earnings Yield | -1217.72 |